Malaria monoclonal antibodies for malaria prevention: Preferred Product Characteristics and clinical development

Members of the Scientific Development Committee for malaria monoclonal antibodies (mAbs) met on 3, 11 and 29 November 2021. The meeting objectives were the following:

1. review the landscape of malaria mAbs and mAbs PPCs for other pathogens;
2. agree on a set of PPC criteria for malaria mAbs;
3. ensure alignment with WHO guidance on mAbs development and PPCs for mAbs for other pathogens (HIV, RSV, COVID) and complementarity with PPCs for malaria vaccines and chemoprevention.